Search results
Showing 1591 to 1605 of 1688 results for carers
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued [GID-TA11041]
In development [GID-TA11163] Expected publication date: TBC
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
In development [GID-TA11007] Expected publication date: TBC
Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)
This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.
Testing strategies for Lynch syndrome in people with endometrial cancer (DG42)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
NICE guidelines are evidence-based recommendations for health and care in England.
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.